GUIDANCE FOR PREVENTION AND TREATMENT OF CYTOMEGALOVIRUS (CMV) in Stem Cell Transplant Recipients at Atrium Health Wake Forest Baptist Updated: Winter 2025

CMV PREVENTION

1. PRIMARY PROPHYLAXIS

- a. Start letermovir between day 0 and day 9 in all CMV R+ patients undergoing allogeneic stem cell transplant.
- b. Letermovir dose: 480 mg PO or IV daily (for detailed dosing recommendations, see *Table 3* below)
- c. Continue prophylaxis with letermovir until day 200
- d. Consider stopping prophylactic letermovir at day 100 for certain patients with lower risk, including the following:
 - 1. Off all immunosuppressive medications
 - 2. No prior CMV reactivation requiring treatment
- e. If letermovir cannot be used for primary prophylaxis, it is NOT generally recommended to use an alternative agent such as valganciclovir, ganciclovir or foscarnet.

2. SECONDARY PROPHYLAXIS

- a. After discontinuation of pre-emptive therapy, consider extending prophylaxis beyond day 200 for patients with one or more of the following risk factors:
 - i. Absolute lymphocyte count $< 100 \text{ cells}/\mu L$
 - ii. CMV infection prior to day 100
 - iii. GVHD requiring steroids equivalent to prednisone 0.5 mg/kg/day or greater
 - iv. Absence of CMV-specific T-cell immunity
- b. Duration of extended prophylaxis should be customized based on patient-specific factors by the treating clinician

CMV TREATMENT

1. PRE-EMPTIVE THERAPY

- a. Monitor all allogeneic stem cell transplant patients with CMV PCR as follows:
 - i. Weekly until Day 100
 - ii. Every visit (or as clinically indicated) until Day 180
 - iii. May continue monitoring beyond Day 180 for patients with GVHD or those remining on immunosuppression (until Day 240 and off immunosuppression)
- b. Pre-emptive therapy should be initiated based CMV viral load and the patient factors outlined in *Figure 1*.




Figure 1. Thresholds for starting pre-emptive therapy based on serial monitoring of CMV PCR. Risk group indicates risk for developing CMV reactivation and/or disease. [†] *Patients who have received post-transplant cyclophosphamide can be considered as having received a T-cell depleted transplant.* [‡] *Consider that patients on high dose steroids may benefit from pre-emptive therapy at a lower CMV PCR threshold*

2. TREATMENT

- a. When initiated, CMV treatment should begin with induction dosing for a minimum of 2 weeks and until the CMV PCR is below the lower limit of quantitation (< 34.5 IU/mL) on 2 weekly laboratory samples
- b. Induction should be followed by 2 weeks of maintenance with the same agent

Table 1. Preferred treatment options for CMV viremia and disease. For detailed dosing information based on renal function, refer to *Table 2* below.

	Treatment Selection			
Pre-engraftment [§]	Foscarnet			
Post-engraftment [†]	Ganciclovir			
	or			
	Valganciclovir (if no issues with GI absorption)			
Treatment Resistant OR Refractory	Maribavir [‡]			

[§] For patients not likely to tolerate foscarnet (e.g. poor renal function, electrolyte disturbances, heart failure or volume overload), maribavir may be considered as an alternative to foscarnet prior to engraftment.

^{\dagger} Engraftment is defined as ANC > 500 cells/µL for 3 days. For patients who develop leukopenia and/or neutropenia on treatment, consider switching therapy to IV foscarnet.

[‡] Should be reserved for patients with CMV PCR \leq 50,000 IU/mL, but may be considered when CMV PCR \leq 100,000 IU/mL; see below for details on specific genotypic resistance mutations and indications for maribavir

3. RESISTANT & REFRACTORY (R/R) TREATMENT

- a. CMV genotype testing should be considered for the following:
 - i. CMV Viral load fails to decline by $> 1 \log_{10}$ after more than 2 weeks of appropriately dosed antiviral therapy
 - ii. Plasma viral load \geq 1000 IU/mL
- b. For suspected CMV resistance, it is recommended to switch drug class, test for genotypic resistance mutations and reduce immunosuppression as much as possible. See *Table 2* below for more detailed management of resistant/refractory CMV.
- c. Treatment of R/R CMV should continue for at least 2-4 weeks and be guided by resolution of symptoms in addition to achieving undetectable CMV DNA on 2 separate assays.

Table 2. Recommended use of anti-CMV agents for resistant/refractory CMV

Use of maribavir for resistant/refractory CMV

Maribavir should be considered the preferred therapy for patients with EITHER refractory CMV OR resistance documented by one or more genotypic mutations. In patients for whom maribavir is not accessible or not clinically appropriate, see the ASTCT recommendations below.

Genotype Result(s)	Management
UL97 mutation [†]	First line: foscarnet
High-level resistance to ganciclovir	Second line: cidofovir
UL97 mutation	First line: high-dose ganciclovir (7.5-10 mg/kg q12h)
Low-level resistance to ganciclovir	Second line: foscarnet OR cidofovir
UL54 mutation	First line: cidofovir (can consider adding adjunctive agents such as
Foscarnet/Ganciclovir resistance	leflunomide, artesunate or clinical trial)
UL54 mutation	First line: foscarnet (can consider adding adjunctive agents such as
Ganciclovir/Cidofovir resistance	leflunomide, artesunate or clinical trial)
UL54 mutation	First line: standard-dose ganciclovir (can consider adding
Foscarnet resistance only	adjunctive agents such as leflunomide, artesunate or clinical trial)
UL54 mutation	First line: foscarnet PLUS high-dose ganciclovir (7.5-10 mg/kg
Ganciclovir, Foscarnet AND	q12h) as tolerated - can consider G-CSF support. (can consider
Cidofovir resistance	adding adjunctive agents such as leflunomide, artesunate or
	clinical trial)
UL56, UL89, UL51 mutations	First line: ganciclovir or foscarnet
Letermovir resistance	
Refractory CMV without know	Optimize dosing of ganciclovir; can consider switch from
resistance mutations	ganciclovir to foscarnet.

[†] Greater than 5-fold increase in ganciclovir IC50




Figure 2. Management of CMV viremia and disease after stem cell transplant.

Table 3. Drug therapies for CMV infection

		Prophylaxis		
Dosing	Side effects	Importan	t Interactions	Notes
CrCl > 10 mL/min: 480mg IV or PO daily	GI: abdominal pain, nausea, vomiting or diarrhea	1. Cyclosporine increases concentrations of letermovir and letermovir increases cyclosporine concentrations.		No activity against HSV/VZV
$CrCl \le 10 \text{ mL/min:}$ No data	Thrombocytopenia, headache, peripheral	administering with cyclos		
	edema			
CrCl < 50 mL/min	-		cole and isavuconazole.)	
		Treatment		
	0			Notes
	Induction	Maintenance		If there is leukopenia or
(neutropenia, consider
			A	foscarnet, and consider G-CSF
		<u> </u>		when feasible
		<u> </u>		
			3. Confusion, headache	
CrCl<10/HD				
	· · · · · ·		_	
CVVHD	~ ~ .	1.25 mg/kg q24h		
	Dosing			Notes
Renal Function (ml/min)	Induction	Maintenance	1.Bone marrow suppression (leukopenia	If there is leukopenia or neutropenia, consider
$CrCl \ge 60$	900 mg q12h	900mg q24h		foscarnet, and consider G-CSF
CrCl 40-59	450mg q12h	450mg q24h	e e	when feasible
CrCl 25-39	450mg q24h	450mg every 2 days		
CrCl 10-24	450mg every 2 days	450mg 2 x week	3. Confusion, headache	
CrCl <10/HD	Use not recommended	· · · ·		
	$CrCl > 10 \text{ mL/min:}$ 480mg IV or PO daily $CrCl \leq 10 \text{ mL/min:}$ No data $Caution with IV$ formulation when $CrCl < 50 \text{ mL/min}$ $CrCl < 50 \text{ mL/min}$ $CrCl > 70$ $CrCl > 70$ $CrCl > 70$ $CrCl 50-69$ $CrCl 10-24$ $CrCl 10-24$ $CrCl < 10/HD$ $CVVHD$ $Renal Function$ (ml/min) $CrCl \geq 60$ $CrCl 40-59$ $CrCl 25-39$	CrCl > 10 mL/min: 480mg IV or PO dailyGI: abdominal pain, nausea, vomiting or diarrheaCrCl \leq 10 mL/min: No dataThrombocytopenia, headache, peripheral edemaCaution with IV formulation when CrCl < 50 mL/min	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $

Renal Function (ml/min/kg) Induction Maintenance 1.Nephrotoxicity (damage to tubular cells) Administer an IV fluid bolus with each dose to reduce renal injury. May add IV Foscarnet (IV) CrCl/kg > 1.1.4 70 mg/kg q12h 90mg/kg q24h 2. Hypomagnesemia and hypocalcemia injury. May add IV CrCl/kg > 0.6-0.8 80 mg/kg q24h 80 mg/kg q24h 3. Genital ulcers 4. Seizures 4. Seizures CrCl/kg > 0.6-0.8 60 mg/kg q24h 60 mg/kg q48h 50 mg/kg q48h 50 mg/kg q48h 50 mg/kg q48h CrCl/kg > 0.4-0.5 50 mg/kg q24h 50 mg/kg q48h 50 mg/kg q48h 60 mg/kg q48h CrCl/kg > 0.4 Use not recommended 1. nausea, vomiting, diarrhea May increase tacrolimus, cyclosporine and sirolimus concentrations Maribavir (PO) Not adjusted for renal dysfunction 1. nausea, vomiting, diarrhea 1. Acute renal failure – monitor creatinine closely & ensure appropriate Cidofovir should only be used after exhausting other treatment options in consultation with an infectious diseases specialist. Cidofovir (IV) 3 hours prior to each dose: Probenecid 1 g PO 8 hours after each dose: Probenecid 1 g PO 3. Carcinogen/teratogen Cidofovir should only be used after exhausting other treatment options in consultation with an infectious	Drug Name	Dosing			Side effects	Notes
Maribavir (PO)400 mg BIDI. nausea, vomiting, diarrhea 2. decreased hemoglobin and platelets 3. taste disturbances 4. increased SCrMay increase tacrolimus, cyclosporine and sirolimus concentrationsDrug NameDosingSide effectsNotesImg/kg/dose IV 3 times weekly for 9 doses. Administer with IV hydration and probenecid to reduce the risk for renal injury.1. Acute renal failure – monitor creatinine closely & ensure appropriate supportive care 2. Neutropenia 3 hours prior to each dose: Probenecid 1 g PO 8 hours after each dose: Probenecid 1 g PO 8 hours after each dose: Probenecid 1 g PO1. Acute renal failure - after each dose: Probenecid 1 g PO 8 hours after each dose: Probenecid 1 g POCidofovir (IV)Cidofovir stoul dose: Probenecid 1 g PO 8 hours after each dose: Probenecid 1 g POCidofovir stoul a generationCidofovir stoul a generationCidofovir special stours	Foscarnet (IV)	(ml/min/kg) CrCl/kg >1.4 CrCl/kg >1-1.4 CrCl/kg >0.8-1 CrCl/kg >0.6-0.8 CrCl/kg >0.5-0.6 CrCl/kg ≥0.4-0.5	90mg/kg q12h 70 mg/kg q12h 50 mg/kg q12h 80 mg/kg q24h 60 mg/kg q24h 50 mg/kg q24h	90mg/kg q24h 70 mg/kg q24h 50 mg/kg q24h 80 mg/kg q24h 60 mg/kg q48h 50 mg/kg q48h 50 mg/kg q48h	to tubular cells)2. Hypomagnesemia and hypocalcemia3. Genital ulcers	with each dose to reduce renal injury. May add IV magnesium and calcium
Maribavir (PO)400 mg BID Not adjusted for renal dysfunctiondiarrhea 2. decreased hemoglobin and platelets 3. taste disturbances 4. increased SCrcyclosporine and sirolimus concentrationsDrug NameDosingSide effectsNotesI mg/kg/dose IV 3 times weekly for 9 doses. Administer with IV hydration and probenecid to reduce the risk for renal injury.1. Acute renal failure – monitor creatinine closely & ensure appropriate supportive care 2. Neutropenia 3. Carcinogen/teratogenCidofovir should only be used after exhausting other treatment options in consultation with an infectious diseases specialist.	Drug Name				Side effects	Notes
Image: Note of the second se	Maribavir (PO)				diarrhea 2. decreased hemoglobin and platelets 3. taste disturbances	cyclosporine and sirolimus
hydration and probenecid to reduce the risk for renal injury.monitor creatinine closely & ensure appropriate supportive careafter exhausting other treatment options in consultation with an infectiousCidofovir (IV)Administer 1 liter bolus of NS before & after cidofovir. 3 hours prior to each dose: Probenecid 2 g PO 1 hour after each dose: Probenecid 1 g PO 8 hours after each dose: Probenecid 1 g POMonitor creatinine closely & ensure appropriate supportive care 3. Carcinogen/teratogenafter exhausting other treatment options in consultation with an infectious diseases specialist.	Drug Name	Dosing			Side effects	Notes
		 hydration and probenecid to reduce the risk for renal injury. Administer 1 liter bolus of NS before & after cidofovir. 3 hours prior to each dose: Probenecid 2 g PO 1 hour after each dose: Probenecid 1 g PO 			monitor creatinine closely& ensure appropriatesupportive care2. Neutropenia	after exhausting other treatment options in consultation with an infectious

DEFINITIONS

Pre-emptive therapy (PET): routine surveillance for active CMV infection in plasma or whole blood and initiation of antiviral treatment triggered by exceeding a threshold viral load.

Primary prophylaxis: initiation of an antiviral medication (e.g. letermovir) before any laboratory or clinical evidence of CMV.

Probable refractory CMV infection: persistent CMV DNA in the blood at the same level or $< 1 \log_{10}$ increase after at least 2 weeks of appropriately dosed anti-CMV therapy.

Refractory CMV infection: increase by $> 1 \log_{10}$ in CMV DNA levels in the blood after at least 2 weeks of appropriately dosed anti-CMV therapy.

Resistant CMV infection: presence of a known viral genetic mutation that decreases the susceptibility to one or more anti-CMV therapies.

Refractory CMV disease: worsening of clinical signs/symptoms and/or progression to CMV end-organ disease after at least 2 weeks of appropriately dosed anti-CMV therapy.

Secondary prophylaxis: initiated following completion of pre-emptive therapy or treatment of CMV disease once CMV DNA has cleared for the purpose or preventing a recurrent infection.

REFERENCES:

- 1. Marty FM, Ljungman P, Chemaly RF, et al. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. *N Engl J Med.* 2017;377:2433-2444.
- 2. Chemaly RF, Ullmann AJ, Stoelben S, et al. Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation. *N Engl J Med.* 2014;370:1781-1789.
- 3. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective. *Biol Blood Marrow Transplant*. 2009;15:1143-1238.
- 4. Einsele H, Ljungman P, Boeckh M. How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation. *Blood*. 2020;135:1619-1629.
- 5. Lin A, Maloy M, Su Y, et al. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience. *Transplant Infect Dis.* 2019;21:e13187
- 6. van der Heiden PL, Kalpoe JS, Barge RM, Willemze R, Kroes AC, Schippers EF. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. *Bone Marrow Transplant*. 2006;37(7):693-698.
- Avery RK, Alain S, Alexander BD, et al; SOLSTICE Trial Investigators. Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial. *Clin Infect Dis*. 2022 Sep 10;75(4):690-701.
- 8. Hakki M, Aitken SL, Danziger-Isakov L, et al. American Society for Transplantation and Cellular Therapy Series: #3 Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation. *Transplant Cell Ther*. 2021 Sep;27(9):707-719.
- Yong MK, Shigle TL, Kim YJ, Carpenter PA, Chemaly RF, Papanicolaou GA. American Society for Transplantation and Cellular Therapy Series: #4 - Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation. *Transplant Cell Ther*. 2021 Dec;27(12):957-967.
- Russo D, Schmitt M, Pilorge S, et al. Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Haematol*. 2024 Feb;11(2):e127-e135.
- Ueda Oshima M, Xie H, Zamora D, et al. Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantation. *Blood Adv*. 2023;7(8):1394-1403.